cbdMD Inc (YCBD) - Net Assets
Based on the latest financial reports, cbdMD Inc (YCBD) has net assets worth $6.11 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.90 Million) and total liabilities ($3.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check YCBD cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.11 Million |
| % of Total Assets | 61.75% |
| Annual Growth Rate | 4.89% |
| 5-Year Change | -97.52% |
| 10-Year Change | N/A |
| Growth Volatility | 111.71 |
cbdMD Inc - Net Assets Trend (2015–2024)
This chart illustrates how cbdMD Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is cbdMD Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for cbdMD Inc (2015–2024)
The table below shows the annual net assets of cbdMD Inc from 2015 to 2024. For live valuation and market cap data, see cbdMD Inc (YCBD) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $1.96 Million | -78.26% |
| 2023-09-30 | $9.03 Million | -71.26% |
| 2022-09-30 | $31.42 Million | -69.53% |
| 2021-09-30 | $103.14 Million | +30.26% |
| 2020-09-30 | $79.18 Million | +110.57% |
| 2019-09-30 | $37.60 Million | +168.23% |
| 2018-09-30 | $14.02 Million | +172.27% |
| 2017-09-30 | $5.15 Million | +1858.96% |
| 2016-09-30 | $-292.73K | -122.92% |
| 2015-09-30 | $1.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to cbdMD Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18093705100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.94K | 0.20% |
| Other Components | $184.03 Million | 9372.81% |
| Total Equity | $1.96 Million | 100.00% |
cbdMD Inc Competitors by Market Cap
The table below lists competitors of cbdMD Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cell Impact AB
ST:CI
|
$6.58 Million |
|
Syncona Limited
LSE:SYNC
|
$6.59 Million |
|
Avenir Telecom S.A
PA:AVT
|
$6.59 Million |
|
Altheora SA
PA:ALORA
|
$6.59 Million |
|
Granada Gold Mine Inc
V:GGM
|
$6.58 Million |
|
Oscar Mitra Sukses Sejahtera Tbk PT
JK:OLIV
|
$6.57 Million |
|
Luminar Technologies
NASDAQ:LAZR
|
$6.57 Million |
|
Interoil Exploration and Production ASA
OL:IOX
|
$6.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in cbdMD Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,031,284 to 1,963,417, a change of -7,067,867 (-78.3%).
- Net loss of 3,700,126 reduced equity.
- New share issuances of 50,001 increased equity.
- Other comprehensive income increased equity by 5,000,000.
- Other factors decreased equity by 8,417,742.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.70 Million | -188.45% |
| Share Issuances | $50.00K | +2.55% |
| Other Comprehensive Income | $5.00 Million | +254.66% |
| Other Changes | $-8.42 Million | -428.73% |
| Total Change | $- | -78.26% |
Book Value vs Market Value Analysis
This analysis compares cbdMD Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.23x to 2.00x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-09-30 | $3.96 | $0.91 | x |
| 2017-09-30 | $25.30 | $0.91 | x |
| 2018-09-30 | $73.20 | $0.91 | x |
| 2019-09-30 | $94.60 | $0.91 | x |
| 2020-09-30 | $78.88 | $0.91 | x |
| 2021-09-30 | $84.48 | $0.91 | x |
| 2022-09-30 | $23.67 | $0.91 | x |
| 2023-09-30 | $4.47 | $0.91 | x |
| 2024-09-30 | $0.46 | $0.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently cbdMD Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -188.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.99%
- • Asset Turnover: 1.84x
- • Equity Multiplier: 5.39x
- Recent ROE (-188.45%) is below the historical average (-185.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -81.14% | -9017.94% | 0.01x | 1.31x | $-1.27 Million |
| 2016 | -923.57% | -165.22% | 1.25x | 4.47x | $-3.39 Million |
| 2017 | -41.28% | -38.85% | 0.63x | 1.68x | $-2.16 Million |
| 2018 | -3.27% | -4.89% | 0.56x | 1.19x | $-1.67 Million |
| 2019 | -120.81% | -192.08% | 0.25x | 2.51x | $-49.19 Million |
| 2020 | 15.92% | 30.09% | 0.38x | 1.40x | $4.68 Million |
| 2021 | -22.68% | -52.60% | 0.36x | 1.21x | $-33.71 Million |
| 2022 | -235.76% | -209.26% | 0.87x | 1.30x | $-77.23 Million |
| 2023 | -253.99% | -94.96% | 1.49x | 1.79x | $-23.84 Million |
| 2024 | -188.45% | -18.99% | 1.84x | 5.39x | $-3.90 Million |
Industry Comparison
This section compares cbdMD Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $196,265,727
- Average return on equity (ROE) among peers: -56.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| cbdMD Inc (YCBD) | $6.11 Million | -81.14% | 0.62x | $6.58 Million |
| Aurora Cannabis Inc (ACB) | $605.09 Million | 0.26% | 0.40x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $32.61 Million | -16.39% | 10.55x | $340.21 Million |
| Alkermes Plc (ALKS) | $1.09 Billion | -18.11% | 0.66x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.78 Billion |
| Amphastar P (AMPH) | $427.53 Million | 11.45% | 0.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $20.01 Million | -419.73% | 172.53x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.40 Million | -25.93% | 0.43x | $202.62 Million |
| ANI Pharmaceuticals Inc (ANIP) | $2.63 Million | -101.06% | 0.31x | $1.80 Billion |
About cbdMD Inc
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, ready to drink cans, and sleep, focus, and calming aids. It also provides veterinarian-formulated p… Read more